凝血因子IX的结构解析及其对乙型血友病治疗的影响
本综述分析凝血因子IX的结构与功能关系,阐明其经蛋白水解激活为因子IXa后,需与辅因子VIIIa及底物因子X多重特异相互作用才能获得完全酶活性,并可与抑制剂、血管外蛋白及细胞受体结合被清除。综述指出基于结构理解可设计循环半衰期更长、活性更高、抗抑制及不依赖VIIIa的修饰因子IX,有望改善乙型血友病治疗。
要点
- 因子IX经蛋白水解激活为IXa后,结构重排不足以产生完全活性,需与VIIIa及因子X相互作用。
- 因子IXa可与抑制剂、血管外蛋白及细胞受体结合而被清除。
- 基于结构的修饰因子IX可延长循环滞留、提高活性、抗抑制甚至不依赖VIIIa。
核心结论
- 理解因子IX功能与结构的关系可指导开发循环滞留时间更长、功能活性更高、抗抑制甚至不依赖VIIIa的修饰因子IX,有望显著改善乙型血友病治疗。
研究设计与样本
- 综述,分析凝血因子IX结构与功能相关的分子机制。
主要发现
- 因子IX经蛋白水解激活为因子IXa后的结构重排不足以产生完全活性的因子IXa。
- 因子IXa、辅因子VIIIa与生理底物因子X之间的多重特异相互作用进一步改变因子IXa结构以实现完全酶活性。
- 因子IXa还可与抑制剂、血管外蛋白及细胞受体相互作用,从而将因子IX(a)从循环中清除。
关键数值与推荐
- 乙型血友病通过血浆来源蛋白、重组生物等效蛋白或基因治疗替换缺失的因子IX进行治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coagulation factor IX plays a central role in hemostasis through interaction with factor VIIIa to form a factor X-activating complex at the site of injury. The absence of factor IX activity results in the bleeding disorder hemophilia B. This absence of activity can arise either from a lack of circulating factor IX protein or mutations that decrease the activity of factor IX. This review focuses on analyzing the structure of factor IX with respect to molecular mechanisms that are at the basis of factor IX function. The proteolytic activation of factor IX to form activated factor IX(a) and subsequent structural rearrangements are insufficient to generate the fully active factor IXa. Multiple specific interactions between factor IXa, the cofactor VIIIa, and the physiological substrate factor X further alter the factor IXa structure to achieve the full enzymatic activity of factor IXa. Factor IXa also interacts with inhibitors, extravascular proteins, and cellular receptors that clear factor IX(a) from the circulation. Hemophilia B is treated by replacement of the missing factor IX by plasma-derived protein, a recombinant bioequivalent, or via gene therapy. An understanding of how the function of factor IX is tied to structure leads to modified forms of factor IX that have increased residence time in circulation, higher functional activity, protection from inhibition, and even activity in the absence of factor VIIIa. These modified forms of factor IX have the potential to significantly improve therapy for patients with hemophilia B.
引用
- Bos MHA, van Diest RE, Monroe DM, et al. Blood coagulation factor IX: structural insights impacting hemophilia B therapy. Blood. 2024. PMID: 38996207. doi:10.1182/blood.2023023276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。